Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition

Analytical validation and amyloid-status discrimination of a high-throughput, research-use-only plasma p-Tau217 immunoassay

P. Wynveen A. Becker S. Levin B. Dumke N. Hoekstra K. Hoffmann C. Knutson J. Lengfeld P. Li J. Radcliff K. Bhatt H. Zetterberg A. Benedet M. Holland C. Carlson J. Hinson
Sep 2026 · medRxiv · 0 citations
Medicine

TL;DR

Findings support the Access p-Tau217 (RUO) assay as a robust, high-throughput assay for plasma biomarker-based discrimination of PET-defined amyloid pathology in AD applications.

DOI Semantic Scholar
View source

Similar papers

Review Open access Aug 2026

PLASMA p-tau217 AS A MINIMALLY INVASIVE BIOMARKER FOR ALZHEIMER’S DISEASE DIAGNOSIS: ANALYTICAL PLATFORMS, DIAGNOSTIC PERFORMANCE, AND CLINICAL IMPLEMENTATION CHALLENGES

Plasma p-tau217 showed high diagnostic performance for identifying amyloid and tau pathology and generally outperformed other phosphorylated tau isoforms, but it should not be interpreted as a stand-alone test.

Oliwia Lenkiewicz, Julia Lenkiewicz, Z. Chmielewska et al. · 0 citations
Review Aug 2026

Diagnostic accuracy of plasma p-tau217 against amyloid PET: A meta-analysis of technical platform variability and ratio versus single marker comparisons

The p-tau217/Aβ42 ratio approximately doubled the diagnostic odds ratio compared with p-tau217 alone and its application in clinical practice is supported by the fact that the p-tau217/Aβ42 ratio performed much better than p-tau217 alone.

Chao-Wei Yuan, Hui Zhang, Xudong Chen et al. · 0 citations
Aug 2026

Analytical validation and clinical performance of a chemiluminescence immunoassay panel for plasma biomarkers in Alzheimer's disease: a preliminary study.

BACKGROUND Alzheimer's disease (AD) poses a growing global health challenge, highlighting the urgent need for reliable and minimally invasive diagnostic tools. This study aimed to develop and comprehensively validate an automated chemiluminescence immunoassay (CLIA) for the simultaneous quantification of six core plasm...

Xi-Meng Chen, Wen-Can Jiang, Li-Juan Wang et al. · 0 citations
Sep 2026

Validation of plasma core biomarkers of Alzheimer's disease: A multicenter study in usual practice conditions

Plasma p-tau217 is established as a first-choice biomarker for the early detection of AD pathology in specialized clinical settings, displaying excellent diagnostic accuracy and minimal site-related variability.

A. Sánchez-Soblechero, A. Villarejo, M. Carreras et al. · 0 citations
Open access Aug 2026

Plasma p-tau217 as a two-cutoff approach to improve tau-PET screening and trial recruitment in Alzheimer’s disease

Blood-based biomarkers could broaden access to Alzheimer’s disease diagnostics, but their ability to approximate tau PET, and to address gray-zone results, remains uncertain. We evaluated plasma p-tau217 against tau PET using a harmonized ADNI baseline cohort and an independently derived temporal meta-ROI tau-PET thres...

Yasaman Abtahi, Nikki Ghadiminia, Hamide Nasiri et al. · 0 citations
Open access Sep 2026

Plasma biomarker strategies to reduce diagnostic uncertainty in p-tau217–based assessment of CSF amyloid positivity in secondary-care patients with MCI

Plasma p-tau217 accurately reflects amyloid pathology, but dual-cutoff strategies leave a non-negligible grey zone requiring confirmatory testing. We evaluated whether integrating plasma Aβ measurements could reduce diagnostic uncertainty in patients with mild cognitive impairment (MCI). Plasma p-tau217 was...

M. Pascual-Lucas, L. Sarasa, N. Fandos et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.